Literature DB >> 8476221

Human lung and bladder carcinoma tumors as compared to their adjacent normal tissue have elevated AP-1 activity associated with the retinoblastoma gene promoter.

S Linardopoulos1, E Papadakis, D Delakas, V Theodosiou, A Cranidis, D A Spandidos.   

Abstract

Examination of the nucleotide sequence of the retinoblastoma (Rb) promoter revealed the presence of a DNA region highly homologous to the recognition site for the cellular transcription factor AP-1. A pair of complementary oligonucleotides containing the AP-1 site was synthesized and used in gel retardation assays to determine the role of the AP-1 protein in the regulation of the Rb gene expression. Using nuclear extracts from Hela cells as well as from lung and bladder tumors, we found specific binding of the AP-1 protein to this oligonucleotide. This binding is elevated in Hela cells, in 10/13 lung and 3/8 bladder tumors as compared to adjacent normal tissue. These results suggest that AP-1 could be implicated in Rb gene transcriptional regulation through its interaction with the AP-1 binding site of the Rb gene promoter.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8476221

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

Review 1.  Emerging roles of ATF2 and the dynamic AP1 network in cancer.

Authors:  Pablo Lopez-Bergami; Eric Lau; Ze'ev Ronai
Journal:  Nat Rev Cancer       Date:  2010-01       Impact factor: 60.716

2.  Expression of Rb2/p130 in breast and endometrial cancer: correlations with hormone receptor status.

Authors:  K Milde-Langosch; C Goemann; C Methner; G Rieck; A M Bamberger; T Löning
Journal:  Br J Cancer       Date:  2001-08-17       Impact factor: 7.640

3.  Signaling of MK2 sustains robust AP1 activity for triple negative breast cancer tumorigenesis through direct phosphorylation of JAB1.

Authors:  Haoming Chen; Ravi Padia; Tao Li; Yue Li; Bin Li; Lingtao Jin; Shuang Huang
Journal:  NPJ Breast Cancer       Date:  2021-07-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.